The global human embryonic stem cell market size was estimated to be USD 2.83 billion in 2023 and is expected to reach at USD 7.87 billion by 2034 with a CAGR of 9.74% during the forecast period 2024-2034. Surge in number of clinical trials, rising adoption of stem cell therapies, increasing government funding for the development of regenerative medicine, growing prevalence of cardiac & malignant diseases, surge in demand for regenerative medicines, rising prevalence of genetic disorders, and increasing investment by major market players for the expansion of stem cell-based therapies are some of the key factors boosting the market growth.
Increasing investment by major market players for the expansion of stem cell-based therapies is predicted to boost the market growth during the forecast period. Significant investments are made in the field of human embryonic stem cell-based therapeutics. In developed nations, funding for the advancement of regenerative medicine has been on the rise, driven by its potential applications in areas like organ transplants, tissue engineering, and a range of other uses. For instance, in January 2022, Cellino Biotech, a company specializing in cell therapy manufacturing, secured $80 million in funding through a Series A financing round. The company's objective is to broaden availability of stem cell-based treatments by establishing the world's inaugural independent human cell foundry by 2025.
By application, stem cells biology research was the highest revenue-grossing segment in the global human embryonic stem cell market in 2023 owing to rising prevalence of cardiac & malignant diseases such as Parkinson's disease & Cancer and increasing funding for research. For instance, in April 2022, TreeFrog Therapeutics has introduced The Stem Cell SpaceShot Grant, offering $100,000 in research funding dedicated to the advancement of stem cell biology and regenerative medicine. Additionally, regenerative medicine is predicted to grow at fastest CAGR during the forecast period owing to the growing demand for regenerative medicine, increasing research & development activities, rising technological advancements, and surge in launch of advanced therapies.
By end-user, research was the highest revenue-grossing segment in the global human embryonic stem cell market in 2023 owing to rising prevalence of chronic & genetic disorders and growing research activities on stem cell. Additionally, clinical trials is predicted to grow at fastest CAGR during the forecast period owing to the rising focus on development of innovative treatments, increasing regulatory approvals, and surge in number of clinical trials of novel therapies. For instance, in April 2022, In partnership with several clinical screening locations around the US, Aspen Neuroscience, Inc. has started a ground-breaking patient screening research. This Trial-Ready Cohort Study marks a preliminary phase toward submitting an Investigational New Drug (IND) application to the United States Food & Drug Administration for ANPD001, and for researching iPSC-derived cell replacement treatments targeting Parkinson's disease.
North America region is anticipated for the highest revenue share during the forecast period owing to the growing research & development activities, surge in prevalence of chronic diseases & genetic disorders, rising research funding for the development of various therapies, and increasing investment by major market players. For instance, in May 2022, Researchers from UBC Medicine have secured funding exceeding $2.5 million from Canada's Stem Cell Network to propel forward six initiatives focused on regenerative medicine research and clinical trials. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the rising burden of chronic diseases, growing demand for regenerative medicines, and increasing government support for research & development activities. For instance, in February 2022, To bolster advancements in regenerative medicine research within the nation, the Indian government has facilitated the establishment of cutting-edge stem cell research centers in 40 prominent healthcare research and educational institutions. Additionally, an expenditure of approximately Rs. 8.13 crore has been allocated through the Indian Council of Medical Research (ICMR) for specific projects.
Increasing investment by major market players for the expansion of stem cell-based therapies is predicted to boost the market growth during the forecast period. Significant investments are made in the field of human embryonic stem cell-based therapeutics. In developed nations, funding for the advancement of regenerative medicine has been on the rise, driven by its potential applications in areas like organ transplants, tissue engineering, and a range of other uses. For instance, in January 2022, Cellino Biotech, a company specializing in cell therapy manufacturing, secured $80 million in funding through a Series A financing round. The company's objective is to broaden availability of stem cell-based treatments by establishing the world's inaugural independent human cell foundry by 2025.
By application, stem cells biology research was the highest revenue-grossing segment in the global human embryonic stem cell market in 2023 owing to rising prevalence of cardiac & malignant diseases such as Parkinson's disease & Cancer and increasing funding for research. For instance, in April 2022, TreeFrog Therapeutics has introduced The Stem Cell SpaceShot Grant, offering $100,000 in research funding dedicated to the advancement of stem cell biology and regenerative medicine. Additionally, regenerative medicine is predicted to grow at fastest CAGR during the forecast period owing to the growing demand for regenerative medicine, increasing research & development activities, rising technological advancements, and surge in launch of advanced therapies.
By end-user, research was the highest revenue-grossing segment in the global human embryonic stem cell market in 2023 owing to rising prevalence of chronic & genetic disorders and growing research activities on stem cell. Additionally, clinical trials is predicted to grow at fastest CAGR during the forecast period owing to the rising focus on development of innovative treatments, increasing regulatory approvals, and surge in number of clinical trials of novel therapies. For instance, in April 2022, In partnership with several clinical screening locations around the US, Aspen Neuroscience, Inc. has started a ground-breaking patient screening research. This Trial-Ready Cohort Study marks a preliminary phase toward submitting an Investigational New Drug (IND) application to the United States Food & Drug Administration for ANPD001, and for researching iPSC-derived cell replacement treatments targeting Parkinson's disease.
North America region is anticipated for the highest revenue share during the forecast period owing to the growing research & development activities, surge in prevalence of chronic diseases & genetic disorders, rising research funding for the development of various therapies, and increasing investment by major market players. For instance, in May 2022, Researchers from UBC Medicine have secured funding exceeding $2.5 million from Canada's Stem Cell Network to propel forward six initiatives focused on regenerative medicine research and clinical trials. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the rising burden of chronic diseases, growing demand for regenerative medicines, and increasing government support for research & development activities. For instance, in February 2022, To bolster advancements in regenerative medicine research within the nation, the Indian government has facilitated the establishment of cutting-edge stem cell research centers in 40 prominent healthcare research and educational institutions. Additionally, an expenditure of approximately Rs. 8.13 crore has been allocated through the Indian Council of Medical Research (ICMR) for specific projects.
Segmentation: Human Embryonic Stem Cell Market Report 2022 - 2033
Human Embryonic Stem Cell Market Analysis & Forecast by Application 2023 - 2034 (Revenue USD Bn)
- Tissue Engineering
- Stem Cell Biology Research
- Toxicology Testing
- Regenerative Medicine
Human Embryonic Stem Cell Market Analysis & Forecast by End-user 2023 - 2034 (Revenue USD Bn)
- Clinical Trials
- Research
- Other
Human Embryonic Stem Cell Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
North America
- U.S.
- Canada
Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Human Embryonic Stem Cell Market: Application Estimates & Trend Analysis
8. Human Embryonic Stem Cell Market: End-user Estimates & Trend Analysis
9. Regional Market Analysis
10. North America Human Embryonic Stem Cell Market
11. Europe Global Human Embryonic Stem Cell Market
12. Asia Pacific Global Human Embryonic Stem Cell Market
13. Latin America Global Human Embryonic Stem Cell Market
14. MEA Global Human Embryonic Stem Cell Market
15. Competitor Analysis
16. Company Profiles
Companies Mentioned
- Thermo Fisher Scientific
- STEMCELL Technologies Inc
- Merck KGaA
- PeproTech Inc.
- ViaCyte Inc.
- Takara Bio Inc.
- Astellas Pharma Inc.
- PromoCell GmbH
- Lineage Cell Therapeutics Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 145 |
| Published | October 2023 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 2.83 Billion |
| Forecasted Market Value ( USD | $ 7.87 Billion |
| Compound Annual Growth Rate | 9.7% |
| Regions Covered | Global |
| No. of Companies Mentioned | 9 |
